Ken Frazier, AP Images
June 2, 2020 11:17 AM EDTUpdated July 15, 06:59 AM
People
R&D
In Focus

Why Mer­ck wait­ed, and what they now bring to the Covid-19 fight

Jason Mast

Editor

Nicholas Kart­so­nis had been run­ning clin­i­cal in­fec­tious dis­ease re­search at Mer­ck for al­most 2 years when, in mid-Jan­u­ary, he got a new as­sign­ment: search­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times